In short
- Diagnosis is clinical. In perimenopause a single blood test can mislead, so symptoms and history lead.
- The first prescription is rarely the final one. Dose and route are adjusted with review.
- Risks and benefits, honestly. They depend on your age, your history and the type of treatment.
- Bone, heart and muscle belong in the plan, not only symptom relief.
Treatment Overview
What is the Women’s Hormone Membership?
It is continuous care through perimenopause and menopause: a long first consultation, an honest discussion of the options, treatment initiation and titration where hormone therapy is appropriate, and scheduled reviews with earlier review after starting or changing treatment.
It also covers the screening and prevention appropriate to your age, including bone and cardiovascular risk, and access between reviews for side effects, bleeding patterns or questions that should not wait.
How diagnosis is approached
In perimenopause, hormone levels fluctuate considerably and a single blood test can be misleading. Diagnosis rests mainly on your symptoms and your history, with blood tests used to exclude other causes such as thyroid disease, anaemia or iron deficiency rather than to confirm what your symptoms already show. Some symptoms attributed to hormones turn out to have another explanation, and finding that out is part of the assessment rather than a detour from it.
Who Is a Good Candidate?
- You are in your forties or fifties with symptoms you suspect are hormonal and want a proper assessment.
- You have been told your blood tests are normal but you do not feel well, and nobody has explained what perimenopause looks like on a blood test.
- You are already on hormone replacement therapy and want the dose, the route and the progestogen reviewed by a physician who will follow it up.
- You want to discuss the risks and benefits of HRT honestly, with your own history taken into account.
- You want a plan that also covers bone, cardiovascular and metabolic health, not only symptom relief.
- You have unexplained vaginal bleeding. That needs investigating before any hormone treatment.
- You have a history of breast cancer, or an oestrogen dependent cancer, which requires specialist input and usually rules out systemic hormone therapy.
- You have active or recent venous thromboembolism, or active liver disease, both of which change what is possible.
What Happens During the Consultation
-
1
Symptoms and history
Symptom history, cycle history, medical and family history, and what you have already tried. How the symptoms affect your sleep, your work and your relationships matters as much as the list itself.
-
2
Examination and investigation
Examination and the investigations your case requires. Blood tests are used to exclude thyroid disease, anaemia and iron deficiency rather than to confirm perimenopause, and screening appropriate to your age is checked and arranged.
-
3
Options, risks and your decision
Hormone therapy, non hormonal treatments and what lifestyle change realistically contributes, with the risks and benefits set against your own history. The decision is documented so you can revisit the reasoning later.
-
4
Starting and titrating
Where treatment is chosen, you start with a route and a dose that suit your history, with an early review already booked. The first prescription is rarely the final one and the plan says so from the outset.
Program Structure & Follow-Up
What does the follow up look like?
Follow up matters because treatment is adjusted over time and because side effects and bleeding patterns need reviewing rather than tolerating.
- Early review after starting or changing treatment, usually within the first three months.
- Regular reviews thereafter, covering symptom control, bleeding pattern, side effects, blood pressure and whether the route or dose still fits.
- Access between reviews for bleeding, side effects or questions that should not wait.
- Prevention reviewed alongside, including bone density risk, cardiovascular risk, blood pressure and lipids.
This period of life is also when body composition shifts even without a change in weight, so muscle mass, strength training and protein intake belong in the plan. Sleep is treated as a clinical problem in its own right, because poor sleep amplifies almost every other symptom.
Why does hormone therapy need a yearly review?
Because the balance of benefit and risk shifts over time, and it shifts with you, not with the prescription.
Two things change. Your own risk changes: age, blood pressure, weight, new diagnoses, a family history that becomes relevant. And the need changes: symptoms that justified treatment at 51 may have settled by 56, and continuing then is a decision rather than a default.
There is also a practical reason. Observational data suggest 40 to 50 percent of women who start hormone therapy stop within a year and 65 to 75 percent within two years, often without any input from a doctor. A planned review is what prevents stopping badly.
What is actually checked?
The review covers symptoms, dose, bleeding, blood pressure, breast screening and anything that has changed your risk.
| What | Why |
|---|---|
| Symptoms and whether they still need treating | This is the question the review exists to answer |
| Dose and preparation | Doses often come down over time. Lower doses mean less bleeding and breast tenderness |
| Bleeding pattern | Unscheduled bleeding, or bleeding after a spell of none, needs investigating |
| Blood pressure and weight | Both feed into cardiovascular risk and both drift |
| Breast screening | Mammograms continue as usual on hormone therapy |
| Personal and family history | New diagnoses in you or a first-degree relative can change the calculation |
| Bone risk | Particularly relevant if a stop is being planned, because bone loss resumes |
Blood tests are not automatic. They are done where something has changed or where a baseline needs repeating, not as an annual ritual.
Why are hormone levels not measured?
Because the dose is judged by whether your symptoms are controlled and whether you tolerate the treatment, not by a number.
Routine oestradiol levels are not used to steer standard hormone therapy. Dosing steered by hormone levels, and by saliva tests in particular, is the approach used by compounded hormone programmes, and it has no evidence behind it.
Compounded hormone mixtures and saliva testing are not used here, and the reason is not brand preference. What is wrong with compounded hormones.
When should treatment stop?
The standard recommendation has been five years, and not beyond age 60, but that is a starting point rather than a rule.
The case against a fixed cut-off is simply that symptoms outlast it. Hot flushes persist for as long as 10 to 20 years after the last period in many women, and over 40 percent of women aged 60 to 65 still have them badly enough to affect sleep and quality of life. Both the Menopause Society and the American College of Obstetricians and Gynecologists say use should be individualised and not discontinued solely on age.
What does change with age is the risk side. Starting fresh at 65 or older is advised against by the American Geriatrics Society, and from 70 treatment is avoided. Between 60 and 69 it is an individual judgement. Continuing treatment that is already working is a different question from starting it.
Women whose menopause came before 40 are a separate case: treatment continues at least to around age 50 to 51, and the usual risk conversation begins only at that point.
When treatment starts matters more than how long it lasts. Within ten years of the last period the balance looks different than it does at 70. Why timing changes the picture.
Is it better to taper or to stop?
The evidence is genuinely mixed, and the practical answer is that a planned reduction is easier to live with.
Survey data favour tapering. A randomised trial of 91 women on hormone therapy for at least three years found symptoms worse in the abrupt group for the first three months, worse in the taper group at six months, and no difference by 9 to 12 months. A similar proportion restarted treatment either way, 42 percent after stopping abruptly and 36 percent after tapering.
What is clear is that stopping suddenly brings symptoms back. In a survey of 8,405 women from the Women’s Health Initiative who were told to stop abruptly when the trial ended, moderate to severe symptoms appeared in 56 percent of those who had flushes at baseline, against 22 percent on placebo, and in 21 percent of those who had not had flushes, against 5 percent.
In practice, a taper on tablets reduces by one tablet a week every few weeks; on a patch it steps down through the available strengths over three to six months, and over a year if the first attempt fails. The progestogen comes down on the same schedule. A nonhormonal medicine is often started alongside the taper to cover returning flushes.
What if you want to continue past 60?
That is a reasonable option where symptoms persist and the risk profile allows it, and it is a deliberate decision rather than a drift.
Where extended use is chosen, treatment is restarted or continued at the lowest dose that works, and a future attempt to stop is planned rather than abandoned. That plan is revisited each year.
For a healthy woman starting in her fifties the absolute numbers are small, and they differ for oestrogen alone and oestrogen with a progestogen. The risks in absolute numbers.
What if symptoms come back after stopping?
First the nonhormonal options are tried, and if they do not give adequate relief, hormone therapy can be resumed at the lowest dose that works in carefully selected women.
There is no reliable way to tell in advance whether returning flushes will settle quickly or persist, which is why a fixed waiting period is not imposed before deciding.
Where oestrogen is not an option, the tested alternatives are specific antidepressants, gabapentin and the newer neurokinin blockers, not supplements. The nonhormonal options.
Two other things happen when treatment stops and belong in the conversation: bone loss resumes, and breast cancer risk falls back.
The treatments followed in this membership: HRT patches and oestrogen gel, HRT tablets, vaginal oestrogen and non-hormonal treatment. All menopause care: Menopause & HRT Clinic Dubai.
Benefits, Limits & Safety
Benefits, risks and how they are weighed
Hormone therapy is the most effective treatment for vasomotor symptoms such as hot flushes and night sweats, and it also helps genitourinary symptoms, sleep and bone density. Those benefits are well established.
- Risks depend on your situation, specifically your age, your time since menopause, your personal and family history, and the type and route of treatment. Transdermal oestrogen carries a lower venous thrombosis risk than oral.
- Breast cancer risk with combined therapy is small in absolute terms and related to duration of use. It is discussed with numbers rather than headlines.
- Certain histories require particular caution or make systemic hormone therapy unsuitable, and that is assessed before anything is prescribed.
- Unexplained bleeding is investigated first, always.
What treatment can change
Hormone therapy is the most effective treatment available for hot flushes and night sweats, and it also improves genitourinary symptoms, sleep quality and bone density. Effects on mood and cognition vary between women.
How you are followed
An early review within the first three months of starting or changing treatment, then regular reviews covering symptoms, bleeding pattern, blood pressure and side effects, alongside age appropriate screening and bone and cardiovascular risk.
When hormone therapy is not used
Unexplained vaginal bleeding until investigated, a history of breast or other oestrogen dependent cancer, active or recent venous thromboembolism, active liver disease, and untreated high blood pressure until it is controlled.
Cost & Program Investment
The membership covers physician time, reviews and continuity.Investigations and medication are billed separately and quoted before you decide. The exact figure depends on how much review your treatment needs and is given after the first consultation.
Frequently Asked Questions
Usually not for the diagnosis itself. In perimenopause hormone levels fluctuate so much that a single sample can read normal on a day you feel awful. Blood tests are used to rule out thyroid disease, anaemia and iron deficiency, which cause similar symptoms and are treatable.
That depends on your age, how long since your menopause, your personal and family history, and which type and route is used. For most healthy women starting within ten years of menopause the balance favours treatment, and your own numbers are discussed rather than a headline.
Vasomotor symptoms often improve within a few weeks, while sleep and mood can take longer. The first dose is rarely the final one, which is why an early review is booked from the start rather than left for you to chase.
Then the plan is built without them. Non hormonal treatments exist for vasomotor symptoms, and sleep, alcohol, training, protein intake and blood pressure all get addressed regardless. Choosing against hormone therapy does not mean going without care.
Evidence
Where this information comes from
Every figure on this page is taken from the sources below. All of them are free to read, so you can check them yourself.
This page is general medical information and does not replace a personal consultation. Trial results are averages across large groups, not a prediction for any one person.